Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A Long-term Prospective Observational Study in the Netherlands

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis. The study will evaluate the following items: 1. Disease activity 2. Safety and tolerability of aHSCT 3. Changes in the immune system Participants will be subjected to frequent visits for five years after treatment with aHSCT. During these visits, clinical testing, evaluation by questionnaires, MRI scans and blood sampling will be performed.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• All patients approved for treatment with aHSCT in the Netherlands in accordance with the Dutch criteria for aHSCT treatment for RRMS

Locations
Other Locations
Netherlands
Amsterdam UMC
RECRUITING
Amsterdam
St. Antonius Hospital
RECRUITING
Nieuwegein
Contact Information
Primary
Rick Heijnen, MSc
r.m.heijnen@amsterdamumc.nl
+31627228507
Time Frame
Start Date: 2023-08-25
Estimated Completion Date: 2028-09-01
Participants
Target number of participants: 24
Sponsors
Collaborators: St. Antonius Hospital
Leads: Amsterdam UMC, location VUmc

This content was sourced from clinicaltrials.gov